InMode (INMD) Expected to Announce Earnings on Tuesday

InMode (NASDAQ:INMD - Get Free Report) is expected to post its Q4 2024 quarterly earnings results before the market opens on Tuesday, February 11th. Analysts expect InMode to post earnings of $0.59 per share and revenue of $114.24 million for the quarter. Investors interested in listening to the company's conference call can do so using this link.

InMode Price Performance

Shares of NASDAQ INMD traded down $0.21 during midday trading on Friday, reaching $18.04. 1,220,008 shares of the stock were exchanged, compared to its average volume of 935,887. InMode has a 12 month low of $14.87 and a 12 month high of $26.80. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of 9.75 and a beta of 2.13. The business has a 50-day simple moving average of $17.39 and a two-hundred day simple moving average of $17.21.

Analyst Ratings Changes

INMD has been the topic of a number of recent research reports. Needham & Company LLC reissued a "hold" rating on shares of InMode in a research report on Tuesday. Barclays raised their price target on InMode from $26.00 to $29.00 and gave the company an "overweight" rating in a research note on Wednesday. Finally, BTIG Research assumed coverage on InMode in a research note on Thursday, October 17th. They set a "buy" rating and a $25.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $23.00.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.